Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2024 | Developing targeted therapies for urachal and non-urachal adenocarcinoma

Antonio Cigliola, MD, IRCCS San Raffaele Hospital, Milan, Italy, comments on potential treatment strategies for urachal and non-urachal bladder adenocarcinoma. A study assessing genomic alterations in both forms of bladder adenocarcinoma showed that urachal adenocarcinoma was more similar to colorectal cancer and non-urachal adenocarcinoma was more similar to urothelial carcinoma. Treatments based on the respective cancers they are similar to are, therefore, under consideration. Potential druggable targets for both adenocarcinomas include PIK3CA and ERBB2. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.